當(dāng)?shù)貢r間2025年11月7日- 10日，全球心血管領(lǐng)域頂級學(xué)術(shù)盛會—— 美國心臟協(xié)會科學(xué)年會（2024 AHA）將在新奧爾良重磅召開，為全球醫(yī)者打造沉浸式學(xué)術(shù)交流平臺。作為大會核心亮點，組委會精心設(shè)置12場“特色科學(xué)研究（Featured Science）專場”，屆時將集中發(fā)布72項具有里程碑意義的心血管臨床研究成果，涵蓋肥厚型心肌病（HCM）、動靜脈疾病、心力衰竭、人工智能（AI ）在心血管領(lǐng)域的應(yīng)用等關(guān)鍵領(lǐng)域，為全球醫(yī)者呈現(xiàn)兼具創(chuàng)新性與臨床價值的研究成果，助力心血管疾病診療升級。

HCMS.FS 肥厚型心肌?。℉CM）特色科學(xué)研究專場

北京時間：11月8日7:00

Effect of Mavacamten on Measures of Cardiopulmonary Exercise Testing: An Analysis of the ODYSSEY-HCM Randomized Trial

ODYSSEY-HCM隨機試驗再分析：瑪伐凱泰對心肺運動測試指標(biāo)的影響

Polygenic Risk Enhances Penetrance and Prognosis in Hypertrophic Cardiomyopathy: Insights from a US-based Multi-Ancestry Cohort

基于美國多種族隊列的研究洞見：多基因風(fēng)險增強HCM外顯率及對預(yù)后的影響

MAPLE-HCM - Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy

MAPLE-HCM試驗：Aficamten vs 美托洛爾單藥，對梗阻性HCM患者報告健康狀態(tài)的影響

ODYSSEY-HCM - Effect of selected baseline characteristics and exposure on efficacy and safety of mavacamten: A Post-Hoc Analysis from the ODYSSEY trial

ODYSSEY試驗事后分析：基線特征與藥物暴露量對瑪伐凱泰療效和安全性的影響

FS.01 動靜脈困境：靜脈血栓栓塞（VTE）與外周動脈疾?。≒AD）

北京時間：11月8日 22:45

ROXI – Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials

ROXI-VTE-I 和ROXI-VTE-II試驗：兩種作用機制不同的FXI抗體（REGN9933與REGN7508）用于膝關(guān)節(jié)置換術(shù)后靜脈血栓栓塞預(yù)防

PERMET – Metformin for walking impairment in peripheral artery disease: The PERMET Randomized Clinical Trial

PERMET隨機臨床試驗：二甲雙胍能否用于改善PAD患者的步行功能障礙

Foot-PAD – A Double-Blind, Randomized Placebo-Controlled Trial to determine the effect of a 12-Week Program of Footplate Neuromuscular Electrical Stimulation on Walking Capacity in Patients with Peripheral Artery Disease

Foot-PAD雙盲、隨機、安慰劑對照試驗（12周）：評估足底神經(jīng)肌肉電刺激對PAD患者步行能力的影響

DART – DDCI-01 in Pulmonary Arterial Hypertension: A Multicenter Phase IIa Randomized Active-Controlled Trial

DART IIa期多中心、隨機活性對照試驗：DDCI-01用于肺動脈高壓的治療

SATISFY-JP Trial – Satralizumab, an Anti-Interleukin-6 Receptor Antibody, for Pulmonary Arterial Hypertension with an Activated Immune-Responsive Phenotype: Primary Results from the Phase II Trial

SATISFY-JP II期試驗主要結(jié)果：抗IL-6受體抗體Satralizumab用于免疫反應(yīng)表型激活的肺動脈高壓治療的安全性和有效性

PULSAR, STELLAR, ZENITH - Effect of Sotatercept on Mortality and Major Morbidity Outcomes in Patients with Pulmonary Arterial Hypertension: Pooled Analysis of the PULSAR, STELLAR, and ZENITH Trials

PULSAR、STELLAR、ZENITH試驗匯總分析：Sotatercept對肺動脈高壓患者死亡率和主要發(fā)病率的影響

RESCUE-PTTM – Efficacy and Safety of Imatinib Therapy Administered in Patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A Prospective, Multi-Center Exploratory Clinical Trial

RESCUE-PTTM前瞻性、多中心、探索性試驗：伊馬替尼治療肺腫瘤血栓性微血管?。≒TTM）的安全性和有效性

FS.02 從馬德里到新奧爾良：游行中的心衰試驗

北京時間：11月9日 02:30

Get with the Guidelines Hospital Participation and its Impact on GDMT and HF Outcomes using an Interrupted Time Series Analysis *

中斷時間序列分析*：指南依從性醫(yī)院參與度及其對指南指導(dǎo)藥物治療（GDMT）和心衰結(jié)局的影響

DIGIT-HF – Efficacy and safety of Digitoxin in heart failure with reduced ejection fraction according to age: Insights from DIGIT-HF *

DIGIT-HF試驗再分析：洋地黃毒苷在射血分?jǐn)?shù)降低的心衰（HFrEF）患者中的療效和安全性（按年齡分層分析）*

MAPLE-HCM – Clinical Responses to Aficamten Monotherapy Compared with Metoprolol for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis

MAPLE-HCM應(yīng)答分析試驗：Aficamten vs美托洛爾單藥治療，對HCM結(jié)局與疾病負擔(dān)的臨床反應(yīng)

DAPA ACT HF-TIMI 68 – Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure

DAPA ACT HF-TIMI 68試驗：達格列凈vs安慰劑，對心衰住院患者血壓及癥狀性低血壓的影響

SOTA-P-CARDIA Trial (ATRU-V) – A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes *

SOTA-P-CARDIA（ATRU-V）隨機試驗*：索格列凈用于無糖尿病的射血分?jǐn)?shù)保留的心衰（HFpEF）患者的療效和安全性

SURPASS-CVOT – Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide *

SURPASS-CVOT試驗*：替爾泊肽vs度拉魯肽，對2型糖尿病合并動脈粥樣硬化性心血管疾?。ˋSCVD）患者主要不良心血管事件的影響

FS.03 人工智能在心血管領(lǐng)域的試驗與應(yīng)用

北京時間：11月9日 04:15

DETECT-HF – Multicenter Clinical Study of Remote Speech Analysis to Detect Worsening Heart Failure: Results of the Pivotal DETECT-HF Trial *

DETECT-HF關(guān)鍵性試驗結(jié)果*：遠程語音分析檢測心衰惡化的多中心臨床研究

DAMSUN-HF – Prospective Validation and Real-World Implementation of an AI-Enabled Digital Stethoscope for Detecting Systolic Dysfunction in Low-Resource Settings

DAMSUN-HF試驗：AI數(shù)字聽診器在低資源環(huán)境檢測收縮功能不全的前瞻性驗證與真實世界應(yīng)用

Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF

在基于ECG-AI與PREVENT-HF的多隊列研究匯總分析中，優(yōu)化近期心衰風(fēng)險的識別

ECG2Stroke – ECG deep learning model accurately predicts ischemic stroke risk*

ECG2Stroke試驗*：利用心電圖深度學(xué)習(xí)模型精準(zhǔn)預(yù)測缺血性卒中風(fēng)險

Accuracy of cardiologist reporting of severe aortic stenosis and its impact on clinical management: Insights from decision-support artificial intelligence applied to 28,491 men and women undergoing echocardiography*

基于28491例接受超聲心動圖檢查患者的AI決策支持應(yīng)用洞見 *：AI決策系統(tǒng)對心臟病專家報告的嚴(yán)重主動脈瓣狹窄的準(zhǔn)確性及其對臨床管理的影響

FS.04 心衰生物性與實用性干預(yù)：從當(dāng)下到未來

北京時間：11月9日21:00

ANSWER-HF – A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction

ANSWER-HF隨機對照試驗：沙庫巴曲纈沙坦vs 依那普利，治療慢性恰加斯心肌病伴射血分?jǐn)?shù)降低患者的療效和安全性

DAPA-EAT – Dapagliflozin Reduces Epicardial Adipose Tissue and Myocardial Fibrosis in Subclinical Heart Failure: The DAPA-EAT Trial

DAPA-EAT試驗：達格列凈減少亞臨床心衰患者的心外膜脂肪與心肌纖維化

MAPLE-HCM – Effect of Aficamten versus Metoprolol Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial

MAPLE-HCM試驗：Aficamten vs美托洛爾單藥治療，對梗阻性HCM生物標(biāo)志物的影響

First-in-Human Gene Therapy Trial for Patients with Heart Failure with preserved Ejection Fraction (HFpEF) MUSIC-HFpEF: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction *

MUSIC-HFpEF首次人體基因治療試驗：SERCA2a調(diào)控治療HFpEF*

BioVAT-HF DZHK20 – Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure - BioVAT-HF-DZHK20 – Phase II Interim Data Report *

BioVAT-HF DZHK20 II期試驗中期數(shù)據(jù)報告*：誘導(dǎo)多能干細胞衍生工程的人心肌組織作為終末期心衰生物心室輔助組織的安全性和有效性

COPILOT HF – Main Results of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study

COPILOT HF實用性隨機試驗：心衰最佳治療協(xié)同實施合作項目的主要結(jié)果

FS.05 冠心病的藥物與介入治療進展

北京時間：11月9日 22:15

TARGET-D – A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial

TARGET-D隨機臨床試驗：維生素D水平正?；瘜毙怨诿}綜合征（ACS）患者主要不良心血管事件的影響

ICare-FASTER – Improving Care by Faster Risk-Stratification with High-Sensitivity Point-of-Care Troponin in Patients in the Emergency Department: A Stepped-Wedge Cluster Randomised Trial

ICare-FASTER隨機試驗：急診高危患者應(yīng)用床旁高敏肌鈣蛋白進行快速風(fēng)險分層以改善護理的階梯楔形整群隨機試驗

Heart Matters – The effectiveness of heart attack education in regions at highest-risk – the Heart Matters Stepped-Wedge Randomized Control Trial

Heart Matters試驗：高風(fēng)險地區(qū)心梗健康教育有效性的階梯楔形隨機對照試驗

iSENSE-ACS – Infrared Sensor Evaluation for Noninvasive Screening and Early triage in Acute Coronary Syndromes: The iSENSE-ACS Multicenter Study

iSENSE-ACS多中心試驗：利用紅外傳感技術(shù)進行ACS無創(chuàng)篩查與早期分診

CRTC – An individual patient data meta-analysis of complete versus culprit-lesion only revascularization for acute myocardial infarction involving >8,800 individuals: The Complete Revascularization Trialists’ Collaboration (CRTC) *

CRTC薈萃分析*：在＞8800例急性心?；颊咧?，比較完全血運重建與僅處理罪犯病變策略的療效和安全性

FAMOUS – Long-term follow-up of patients with multivessel coronary artery disease – comparison between Functional, Anatomical, or Medical Only-based Evaluation to Prevent Cardiovascular Events – The FAMOUS Trial

FAMOUS 多支冠脈病變患者的長期隨訪試驗：基于功能學(xué)、解剖學(xué)或單純藥物治療的評估策略，對預(yù)防心血管事件的影響

Beta-Blocker Therapy After Myocardial Infarction in Patients with Preserved Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, CAPITAL-RCT)

多項隨機對照試驗的薈萃分析：心梗后射血分?jǐn)?shù)保留患者進行β受體阻滯劑治療的療效和安全性

NEO-MINDSET – Early Aspirin Withdrawal after Percutaneous Coronary Intervention in Acute Coronary Syndromes With and Without ST-Segment Elevation: Results from the NEO-MINDSET trial

NEO-MINDSET試驗結(jié)果：ST段抬高型與非ST段抬高型ACS患者在經(jīng)皮冠脈介入治療（PCI）后早期停用阿司匹林的療效和安全性

FS.06 泛血管介入：跨血管床解剖與介入治療

北京時間：11月10日 00:50

J-BPA–Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan

J-BPA日本全國前瞻性多中心注冊研究：球囊肺動脈成形術(shù)治療慢性血栓栓塞性肺動脈高壓的療效和安全性

FAIR– Fractional Flow Reserve-guided Renal Artery Stenting in Atherosclerotic Renovascular Hypertension: 1 Year Results of the FAIR Randomized Trial

FAIR隨機試驗1年結(jié)果：血流儲備分?jǐn)?shù)（FFR）指導(dǎo)的腎動脈支架置入治療動脈粥樣硬化性腎血管性高血壓的療效和安全性

COACT–Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation: Five-Year Outcomes *

COACT試驗5年隨訪結(jié)局*：心臟驟停后非ST段抬高患者的冠狀動脈造影評估

OPTIMAL– Prospective, multicenter, open-label, randomized controlled trial of deferred stenting versus prompt stenting in acute occlusion of left main coronary artery: Primary outcomes of the OPTIMAL trial *

OPTIMAL試驗主要結(jié)果*：左主干急性閉塞延期支架置入與即刻支架置入策略的前瞻性、多中心、開放標(biāo)簽、隨機對照試驗

SCAPIS– Coronary CT Angiography in Prediction of Coronary Events *

SCAPIS試驗*：探究冠狀動脈計算機斷層掃描血管造影（CCTA）對冠脈事件的預(yù)測價值

MUSHY PEAS– Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction *

MUSHY PEAS試驗*：冠狀動脈CT斑塊對死亡、心血管死亡和心梗的預(yù)測作用

CONFIRM2– Risk stratification by AI-guided CT coronary atherosclerosis quantification alongside the clinical likelihood of obstructive stenosis. (CONFIRM2)

CONFIRM2試驗：AI指導(dǎo)的CT冠狀動脈粥樣硬化量化聯(lián)合臨床可能性進行風(fēng)險分層

FS.07 心臟代謝綜合征管理的新機遇

北京時間：11月10日 04:15

SPRINT– Arterial Stiffness Mechanisms and Orthostatic Hypotension in The Systolic Blood Pressure Intervention Trial *

SPRINT試驗*：動脈僵硬度機制與體位性低血壓

KARDIA-3– A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease

KARDIA-3試驗：在進行標(biāo)準(zhǔn)治療的伴或不伴慢性腎病的合并心血管疾病或心血管疾病高危的高血壓患者中，對比Zilebesiran與安慰劑的療效和安全性

Bax24– Effect of Baxdrostat on 24-Hour Average Ambulatory Blood Pressure in Patients with Resistant Hypertension: The Bax24 Trial

Bax24試驗：探究進行Baxdrostat治療對耐藥性高血壓患者24小時平均動態(tài)血壓的影響

SURPASS-CVOT– Once-weekly tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease

SURPASS-CVOT試驗：替爾泊肽vs度拉糖肽（每周一次），對2型糖尿病合并心血管疾病患者主要不良心血管事件的影響

TIRZSEMA-CVOT– Cardiovascular Outcomes for Tirzepatide and Semaglutide: A RCT-DUPLICATE Initiative

TIRZSEMA-CVOT試驗：替爾泊肽vs司美格魯肽的心血管結(jié)局（RCT-DUPLICATE倡議）

CORALreef HeFH– Enlicitide, an oral PCSK9 inhibitor, in participants with heterozygous familial hypercholesterolemia: a double-blind, Phase 3, randomized placebo-controlled trial

CORALreef HeFH雙盲、III期、隨機、安慰劑對照試驗：探究口服PCSK9抑制劑Enlicitide治療雜合子家族性高膽固醇血癥的療效和安全性

LIBerate-OLE– Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial (LIBerate-OLE)

LIBerate-OLE試驗：Lerodalcibep在LIBerate-VI試驗后的72周開放標(biāo)簽擴展研究中的長期療效和安全性

ELM– Lifestyle intervention for sustained remission of metabolic syndrome (ELM: Enhanced Lifestyles in the Metabolic Syndrome)

ELM試驗（代謝綜合征促進強化生活方式干預(yù)試驗）：探究生活方式干預(yù)能否促進代謝綜合征持續(xù)緩解

FS.08 電生理特色科學(xué)領(lǐng)域

北京時間：11月10日 21:00

PFA-SHAM– Pulsed Field Ablation versus Sham Ablation to Treat Atrial Fibrillation

PFA-SHAM試驗：脈沖場消融vs假消融，治療心房顫動

MANIFEST-US– Multicenter Study on the Safety of Pulsed Field Ablation in the United States

MANIFEST-US多中心試驗：在美國患者中，探究脈沖場消融的安全性

Strength-Based Exercise is Not Associated with Risk of Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy – Towards Safer Exercise Options

探索更安全的運動選擇：力量訓(xùn)練與致心律失常性心肌病患者的室性心律失常風(fēng)險無關(guān)

Artificial Intelligence Analysis of the 12-lead ECG and Clinical Factors to Predict Out-of-Hospital Cardiac Arrest

結(jié)合AI分析的12導(dǎo)聯(lián)心電圖與臨床因素預(yù)測院外心臟驟停

ACE-PAS– Primary Results from the Post Approval Study of a Next Generation Wearable Cardioverter Defibrillator System: the ACE-PAS Trial

ACE-PAS試驗：新一代可穿戴心臟除顫系統(tǒng)獲批后研究的主要結(jié)局

FLECA-ED– Efficacy and safety of flecainide compared to amiodarone for atrial fibrillation cardioversion in patients with Coronary Artery Disease and preserved ejection fraction

FLECA-ED試驗：氟卡尼vs胺碘酮，用于冠脈疾病合并射血分?jǐn)?shù)保留患者房顫復(fù)律的安全性與有效性

FS.09 流感與新冠科學(xué)領(lǐng)域

北京時間：11月11日 02:00

High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes: The FLUNITY-HD Pooled Analysis*

FLUNITY-HD匯總分析*：高劑量vs 標(biāo)準(zhǔn)劑量流感疫苗對心血管結(jié)局的影響

KP-VACCINATE- Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial

來自KP-VACCINATE大型試驗的洞見：以心血管為重點的宣教可改善流感疫苗接種對心血管-腎臟-代謝護理模式與臨床結(jié)局的影響

DAN-GAL-FLU - Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis (DAN-GAL-FLU (DANFLU-2 and GALFLU))

FLUNITY-HD試驗匯總分析（DAN-GAL-FLU試驗[DANFLU-2和GALFLU]）：高劑量 vs. 標(biāo)準(zhǔn)劑量滅活流感疫苗在ASCVD患者中的有效性

NUDGE-FLU-CHRONIC- Influenza vaccination and risk of cardiovascular events: An instrumental variable analysis of >600,000 participants from the NUDGE-FLU-CHRONIC 1 and 2 trials

NUDGE-FLU-CHRONIC試驗：流感疫苗接種與心血管事件風(fēng)險——基于NUDGE-FLU-CHRONIC 1和2試驗中超過60萬參與者的工具變量分析

CISCO-21- Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial *

CISCO-21試驗 *：COVID-19感染后抗阻運動治療的隨機對照試驗

FS.10 重構(gòu)心臟淀粉樣變診療方案：新型識別、治療和治愈手段

北京時間：11月11日 02:30

AI-SCREEN-CA- Artificial Intelligence-based Software for Checking REal-world Echocardiography to ideNtify hidden Cardiac Amyloidosis: AI-SCREEN-CA *

AI-SCREEN-CA試驗*：基于AI的實時超聲心動圖檢測軟件，或有助于識別隱匿性心臟淀粉樣變

Improving Detection of Transthyretin Cardiac Amyloidosis with AI: A Single-Arm Multicenter Trial*

單臂多中心試驗*：AI或可改善轉(zhuǎn)甲狀腺素蛋白心臟淀粉樣變性（ATTR-CM）的檢測

ATTR-CM- Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy *

ATTR-CM II期隨機、安慰劑、對照、盲法試驗主要結(jié)果*：單克隆抗體Coramitug治療轉(zhuǎn)甲狀腺素蛋白淀粉樣心肌病的療效和安全性

Updated Phase 1 Clinical Trial Outcomes of CRISPR Gene Editing With Nexiguran Ziclumeran In Patients With Transthyretin Amyloidosis With Cardiomyopathy

CRISPR基因編輯療法Nexiguran Ziclumeran治療轉(zhuǎn)甲狀腺素蛋白淀粉樣變性心肌病的I期臨床試驗更新結(jié)果

FS.11 脂質(zhì)治療：從轉(zhuǎn)化到應(yīng)用

北京時間：11月11日04:15

SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia*

血管生成素樣蛋白3（ANGPTL3）抗體SHR-1918用于血脂控制不佳患者*

Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

首次人體I期研究：健康志愿者在注射單劑量LPA靶向siRNA藥物Kylo-11后，脂蛋白(a)呈劑量依賴性持續(xù)降低

Evolocumab and Saphenous Vein Graft Patency Following Coronary Artery Bypass Graft (CABG) Surgery in People with and without Diabetes: A Pre-Specified Analysis of the Randomized Placebo Controlled NEWTON-CABG CardioLink-5 Trial

NEWTON-CABG CardioLink-5隨機安慰劑對照試驗預(yù)設(shè)分析：依洛尤單抗對糖尿病患者和非糖尿病患者CABG術(shù)后大隱靜脈橋通暢率的影響

Effects of Real-Time Notification of AI-Derived Incidental Coronary Artery Calcium on Statin Initiation: the Trial *

NOTIFY-PICTURE試驗*：AI衍生的偶發(fā)冠狀動脈鈣（CAC）實時通知對他汀類藥物啟動的影響

A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program*

退伍軍人事務(wù)部血脂優(yōu)化重塑質(zhì)量改進項目（VALOR-QI）*：高膽固醇血癥管理新方法

Refining ASCVD Risk Stratification Using a Lipid-Derived Index: Multi-Cohort Evidence Beyond Guideline Thresholds

超越指南閾值的多隊列證據(jù)：基于脂質(zhì)衍生指標(biāo)優(yōu)化ASCVD風(fēng)險分層

注：*已接收未確認(rèn)的研究

信源：AHA 官網(wǎng)

醫(yī)脈通是專業(yè)的在線醫(yī)生平臺，“感知世界醫(yī)學(xué)脈搏，助力中國臨床決策”是平臺的使命。醫(yī)脈通旗下?lián)碛小概R床指南」「用藥參考」「醫(yī)學(xué)文獻王」「醫(yī)知源」「e研通」「e脈播」等系列產(chǎn)品，全面滿足醫(yī)學(xué)工作者臨床決策、獲取新知及提升科研效率等方面的需求。